| Autor: |
Dale J, Lange, Mona, Shahbazi, Vincenzo, Silani, Albert C, Ludolph, Jochen H, Weishaupt, Senda, Ajroud-Driss, Kara G, Fields, Rahul, Remanan, Stanley H, Appel, Claudia, Morelli, Alberto, Doretti, Luca, Maderna, Stefano, Messina, Ulrike, Weiland, Stefan L, Marklund, Peter M, Andersen |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Annals of Neurology |
| ISSN: |
1531-8249 |
| Popis: |
Objective Cu/Zn superoxide dismutase (SOD1) reduction prolongs survival in SOD1‐transgenic animal models. Pyrimethamine produces dose‐dependent SOD1 reduction in cell culture systems. A previous phase 1 trial showed pyrimethamine lowers SOD1 levels in leukocytes in patients with SOD1 mutations. This study investigated whether pyrimethamine lowered SOD1 levels in the cerebrospinal fluid (CSF) in patients carrying SOD1 mutations linked to familial amyotrophic lateral sclerosis (fALS/SOD1). Methods A multicenter (5 sites), open‐label, 9‐month‐duration, dose‐ranging study was undertaken to determine the safety and efficacy of pyrimethamine to lower SOD1 levels in the CSF in fALS/SOD1. All participants underwent 3 lumbar punctures, blood draw, clinical assessment of strength, motor function, quality of life, and adverse effect assessments. SOD1 levels were measured in erythrocytes and CSF. Pyrimethamine was measured in plasma and CSF. Appel ALS score, ALS Functional Rating Scale–Revised, and McGill Quality of Life Single‐Item Scale were measured at screening, visit 6, and visit 9. Results We enrolled 32 patients; 24 completed 6 visits (18 weeks), and 21 completed all study visits. A linear mixed effects model showed a significant reduction in CSF SOD1 at visit 6 (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text